Douglas G. Johnson
President at OCAM Solutions, Inc.
Profile
Douglas G.
Johnson is a professional with a doctorate degree from the University of Minnesota.
He is currently the Senior Director-Pharmaceutical Operations at VetDC, Inc. and the President at OCAM Solutions, Inc. Previously, he worked as a Senior Product Manager at Baxter Healthcare Corp., Vice President-Manufacturing at Allos Therapeutics, Inc., and as a Principal at Argonne National Laboratory.
Douglas G. Johnson active positions
| Companies | Position | Start |
|---|---|---|
VetDC, Inc.
 VetDC, Inc. Agricultural Commodities/MillingProcess Industries VetDC, Inc. develops cancer drugs for pets. It is a cancer-focused veterinary biopharmaceutical company developing innovative, underutilized human technologies for use in companion animals. It offers VDC-1101, a novel anti-cancer pro-drug from Gilead Sciences for use in animal cancer. The company was founded by Terry J. Opgenorth in 2009 and is headquartered in Fort Collins, CO. | Corporate Officer/Principal | - |
OCAM Solutions, Inc.
 OCAM Solutions, Inc. Miscellaneous Commercial ServicesCommercial Services OCAM Solutions, Inc. provides consulting services. The private company is based in McLean, VA. | President | - |
Former positions of Douglas G. Johnson
| Companies | Position | End |
|---|---|---|
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Argonne National Laboratory
 Argonne National Laboratory Miscellaneous Commercial ServicesCommercial Services Argonne National Laboratory provides research and technology services. Its research areas include computer science, energy, environmental management, and industrial technology. The company was founded in 1946 and is headquartered in Lemont, IL. | Corporate Officer/Principal | - |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | - |
Training of Douglas G. Johnson
| University of Minnesota | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
VetDC, Inc.
VetDC, Inc. Agricultural Commodities/MillingProcess Industries VetDC, Inc. develops cancer drugs for pets. It is a cancer-focused veterinary biopharmaceutical company developing innovative, underutilized human technologies for use in companion animals. It offers VDC-1101, a novel anti-cancer pro-drug from Gilead Sciences for use in animal cancer. The company was founded by Terry J. Opgenorth in 2009 and is headquartered in Fort Collins, CO. | Process Industries |
Argonne National Laboratory
Argonne National Laboratory Miscellaneous Commercial ServicesCommercial Services Argonne National Laboratory provides research and technology services. Its research areas include computer science, energy, environmental management, and industrial technology. The company was founded in 1946 and is headquartered in Lemont, IL. | Commercial Services |
OCAM Solutions, Inc.
OCAM Solutions, Inc. Miscellaneous Commercial ServicesCommercial Services OCAM Solutions, Inc. provides consulting services. The private company is based in McLean, VA. | Commercial Services |
- Stock Market
- Insiders
- Douglas G. Johnson
